Document is current
Any future updates will be listed below
-
Authors
de Boer, Janneke W. https://orcid.org/0000-0002-0221-1835
Keijzer, Kylie https://orcid.org/0000-0002-8348-0438
van Doesum, Jaap A.
Smit, Nienke A. M.
Brouwers, Adrienne H. https://orcid.org/0000-0003-2698-1516
van Sluis, Joyce https://orcid.org/0000-0003-1908-4518
Lub-de Hooge, Marjolijn N. https://orcid.org/0000-0002-5390-2791
Pierik, Frank R. https://orcid.org/0000-0002-7304-4173
Huls, Gerwin A.
van Dijk, Lisanne V.
Visser, Lydia
Diepstra, Arjan https://orcid.org/0000-0001-9239-1050
Noordzij, Walter
Williams, Simon P.
Ungewickell, Alexander
Elias, Sjoerd G. https://orcid.org/0000-0003-3903-4024
de Vries, Elisabeth G. E. https://orcid.org/0000-0002-8949-7425
Niezink, Anne G. H. https://orcid.org/0009-0009-2860-8767
van Meerten, Tom https://orcid.org/0000-0002-5581-6950
-
Funding
Funding for this research was provided by:
Genentech (made available to the instititution)
- License Information
-
More Information
Article History
Received: 18 September 2025
Accepted: 14 November 2025
First Online: 25 November 2025
Competing interests
: M.N.L.H. reports institutional financial support for advisory boards/consultancy from Merck and institutional financial support for clinical and preclinical studies from Amgen, Bayer, and Servier. L.V.v.D received funding unrelated to this project from NWO ZonMw via the VENI (NWO-09150162010173), individual career development grant, and Dutch Cancer Society Young Investigator Grant (KWF-13529). A.D. received research funding from Takeda. A.U. and S.P.W. are employees and stockholders of Genentech Inc., a member of the Roche group. S.G.E. received teaching fees from MSD. E.G.E.d.V. reports institutional financial support for advisory boards/consultancy from NSABP, Daiichi Sankyo, and Crescendo Biologics and institutional financial support for clinical trials or contracted research grants from Amgen, Genentech, Roche, Bayer, Servier, Regeneron, and Crescendo Biologics. A.G.H.N. received research funding from Siemens and Genentech. T.v.M. received research grants from Genentech, Celgene/BMS, and Siemens made available to the institution; personal fees from Kite/Gilead, Janssen, and Eli Lilly (advisory boards or consultancy); and honoraria from Kite/Gilead and Celgene/BMS (speaker fees). A.H.B. reports research grants from Siemens, paid to the institution, outside submitted work. The other authors declare no competing interests.
